1. Vertex Pharmaceuticals. Vertex and TreeFrog Therapeutics Announce Licensing Agreement and Collaboration to Optimize Production of Vertex's Cell Therapies for Type I Diabetes. 2024. https://investors.vrtx.com/node/32011/pdf
2. Bristol Myers Squibb. Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients Faster. 2024. https://news.bms.com/news/corporate-financial/2024/Bristol-Myers-Squibb-and-Cellares-Announce-a-380M-Worldwide-Capacity-Reservation-and-Supply-Agreement-for-the-Manufacture-of-CAR-T-Cell-Therapies-to-Bring-the-Promise-of-Cell-Therapy-to-More-Patients-Faster/default.aspx
3. Ferring Pharmaceuticals. Ferring Pharmaceuticals and SK Pharmteco Enter into Commercial Gene Therapy Manufacturing Deal. 2024. http://www.ferring.com/ferring-pharmaceuticals-and-sk-pharmteco-enter-into-commercial-gene-therapy-manufacturing-deal/
4. NCT02773849. ADSTILADRIN (=INSTILADRIN) in Patients With High Grade Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC). 2024. https://clinicaltrials.gov/study/NCT02773849
5. Kincell Bio. Expanding our capacity with late-phase facility in Research Triangle Park. 2024. https://kincellbio.com/imugene-and-kincell-bio-announce-strategic-manufacturing-and-process-development-partnership/